Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Eric Benevich Biography and Net Worth

Insider of Neurocrine Biosciences

Eric Benevich was appointed Chief Commercial Officer in May 2015 and is responsible for all aspects of commercial development, marketing and sales of the Neurocrine Biosciences product portfolio. Previously, Mr. Benevich was at Avanir Pharmaceuticals, Inc., from 2005 to 2015, serving most recently as Vice President of Marketing where he was responsible for NUEDEXTA® and commercialization of their CNS pipeline. Mr. Benevich has over 20 years of experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at Peninsula Pharmaceuticals Inc., Amgen and AstraZeneca in the sales and marketing of drugs such as Enbrel®, Epogen® and Prilosec®. Mr. Benevich has a BBA in International Business from Washington State University.

What is Eric Benevich's net worth?: The estimated net worth of Eric Benevich is at least $5.52 million as of April 15th, 2024. Mr. Benevich owns 40,778 shares of Neurocrine Biosciences stock worth more than $5,522,157 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Benevich may own. Additionally, Mr. Benevich receives a salary of $805,000.00 as Insider at Neurocrine Biosciences. Learn More about Eric Benevich's net worth.
How old is Eric Benevich?: Mr. Benevich is currently 59 years old. There are 8 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 66 years old. Learn More on Eric Benevich's age.
What is Eric Benevich's salary?: As the Insider of Neurocrine Biosciences, Inc., Mr. Benevich earns $805,000.00 per year. There are 6 executives that earn more than Mr. Benevich. The highest earning executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who commands a salary of $2,050,000.00 per year. Learn More on Eric Benevich's salary.
How do I contact Eric Benevich?: The corporate mailing address for Mr. Benevich and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Eric Benevich's contact information.
Has Eric Benevich been buying or selling shares of Neurocrine Biosciences?: Eric Benevich has not been actively trading shares of Neurocrine Biosciences during the past quarter. Most recently, Eric Benevich sold 19,818 shares of the business's stock in a transaction on Monday, April 15th. The shares were sold at an average price of $133.36, for a transaction totalling $2,642,928.48. Following the completion of the sale, the insider now directly owns 40,778 shares of the company's stock, valued at $5,438,154.08. Learn More on Eric Benevich's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 44 times. They sold a total of 542,972 shares worth more than $74,251,850.99. The most recent insider tranaction occured on December, 17th when insider Ingrid Delaet sold 1,091 shares worth more than $147,285.00. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 12/17/2024.

Eric Benevich Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/15/2024	Sell	19,818	$133.36	$2,642,928.48	40,778
3/14/2024	Sell	75,000	$139.38	$10,453,500.00	40,778
2/8/2023	Sell	980	$104.12	$102,037.60	34,381
2/6/2023	Sell	1,280	$105.63	$135,206.40	17,879
1/6/2023	Sell	400	$125.00	$50,000.00	15,643
11/30/2022	Sell	50,000	$125.90	$6,295,000.00	15,643
11/10/2022	Sell	100	$125.36	$12,536.00	15,643
11/8/2022	Sell	24,593	$125.33	$3,082,240.69	15,643
10/17/2022	Sell	4,960	$110.82	$549,667.20	15,643
8/16/2021	Sell	5,628	$89.62	$504,381.36
11/12/2020	Sell	2,257	$90.71	$204,732.47	17,405
11/2/2020	Sell	20,595	$96.53	$1,988,035.35	35,969
4/15/2020	Sell	8,632	$94.65	$817,018.80
7/15/2019	Sell	5,835	$87.44	$510,212.40	14,910
6/1/2018	Sell	12,350	$97.34	$1,202,149.00	16,690

Eric Benevich Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $135.42

$134.12

$137.01

50 Day Range

MA: $123.99

$115.08

$136.69

2 Week Range

Now: $135.42

$110.95

$157.98

Volume

2,265,589 shs

Average Volume

884,102 shs

Market Capitalization

$13.71 billion

P/E Ratio

36.31

Dividend Yield

N/A

Beta

0.34

First JFK… next Elon?

From Porter & Company | Ad

I share with you in this special investigative documentary.

Eric Benevich Biography and Net Worth

What is Eric Benevich's net worth?

How old is Eric Benevich?

What is Eric Benevich's salary?

How do I contact Eric Benevich?

Has Eric Benevich been buying or selling shares of Neurocrine Biosciences?

Who are Neurocrine Biosciences' active insiders?

Are insiders buying or selling shares of Neurocrine Biosciences?